ICLIT was not as effective as SCIT in a long term
allergic symptoms
TSS
Short-term efficacy and long-term efficacy were observed for allergic symptoms at the first and third year after treatment in both groups. At baseline, there was no significant difference in TSS between ICLIT group (12.3 (1.9)) and SCIT group (12.8 (2.1)). At 1 year after treatment, TSS in ICLIT and SCIT group was 7.9 (2.9) and 9.1 (1.9), separately, indicating the significant symptom improvement in both groups. At 3 year after treatment, TSS in ICLIT and SCIT group was 7.8 (4.1) and 3.6 (3.7), separately, indicating the significant symptom improvement in both groups. In summary, ICLIT (ICLIT=4.7, SD=2.9) and SCIT (SCIT=3.6, SD=1.9) shared similar short-term efficacy (Comparison of short-term (1 year later) and long-term (3 years later) effects between ICLIT and SCIT. Compared with the two groups, 